William Lewis Sells 79,350 Shares of Insmed Incorporated (NASDAQ:INSM) Stock

Insmed Incorporated (NASDAQ:INSM) CEO William Lewis sold 79,350 shares of the business’s stock in a transaction that occurred on Thursday, February 6th. The shares were sold at an average price of $80.90, for a total value of $6,419,415.00. Following the completion of the sale, the chief executive officer now owns 453,894 shares in the company, valued at $36,720,024.60. The trade was a 14.88 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

William Lewis also recently made the following trade(s):

• On Monday, February 3rd, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $77.94, for a total transaction of $1,461,375.00.
• On Wednesday, January 15th, William Lewis sold 31,805 shares of Insmed stock. The stock was sold at an average price of $70.18, for a total transaction of $2,232,074.90.
• On Friday, January 10th, William Lewis sold 2,978 shares of Insmed stock. The shares were sold at an average price of $63.36, for a total transaction of $188,686.08.
• On Tuesday, January 7th, William Lewis sold 8,218 shares of Insmed stock. The stock was sold at an average price of $66.02, for a total transaction of $542,552.36.
• On Thursday, January 2nd, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $69.84, for a total value of $1,309,500.00.
• On Thursday, December 19th, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $69.91, for a total value of $1,310,812.50.

Insmed Trading Down 1.0 %

Shares of Insmed stock opened at $79.95 on Friday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The firm has a 50-day moving average of $72.79 and a 200-day moving average of $73.10. Insmed Incorporated has a 52-week low of $21.92 and a 52-week high of $82.04. The stock has a market cap of $14.30 billion, a PE ratio of -14.41 and a beta of 1.11.

Institutional Trading of Insmed

Institutional investors have recently bought and sold shares of the business. Dimensional Fund Advisors LP acquired a new stake in shares of Insmed in the second quarter valued at approximately $810,000. Truist Financial Corp bought a new position in Insmed during the 2nd quarter worth $413,000. Park Avenue Securities LLC raised its holdings in Insmed by 28.5% in the 3rd quarter. Park Avenue Securities LLC now owns 5,597 shares of the biopharmaceutical company’s stock valued at $409,000 after acquiring an additional 1,240 shares in the last quarter. GAMMA Investing LLC lifted its position in Insmed by 71.3% during the third quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 224 shares during the period. Finally, Tobam bought a new stake in shares of Insmed during the 3rd quarter worth approximately $464,000.

Analyst Ratings Changes

A number of brokerages have recently issued reports on INSM. Guggenheim upped their price objective on Insmed from $95.00 to $101.00 and gave the stock a “buy” rating in a research note on Friday. HC Wainwright reaffirmed a “buy” rating and set a $90.00 price target on shares of Insmed in a research report on Friday, November 1st. Morgan Stanley boosted their price objective on shares of Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a research note on Thursday. Truist Financial reiterated a “buy” rating and issued a $105.00 target price (up from $100.00) on shares of Insmed in a research note on Friday, November 1st. Finally, JPMorgan Chase & Co. lifted their price target on Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a report on Friday. One analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $85.00.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.